Sam Fazeli
speaker
906 appearances
5 recordings
1 series
first heard Oct 2025
last heard 31 Mar
Sam Fazeli’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.
Appearances
and make some money for the companies that are developing them otherwise what's the point uh last couple of minutes um mna 2026 five turned out to be okay or good i would say in terms of pharma buying biotechs pharma biotechs buying biotechs genmab and and um and mares for example what's your feel for 26 do you feel the momentum in the second half of the year is going to be kept
Is that what you're hearing?
I mean, I've got friends on the sales side.
I don't know if you follow the Biotech Hangout ever that I get involved with on Fridays sometimes.
Southside friends out of the US, Lear Inc.
friends, or Cantor, Karen, Jeffrey's used to come along, but he's moved.
And I think we had a range of something between 15 to 50 companies potentially IPOing in 2026.
And are you optimistic that we're going to be able to see some of this momentum in the follow-on market, potentially wash through to IPOs, essentially, eventually in 2026?
Antoine, again, it just reminded me how wonderful it is to talk to you either on a panel or together like this.
We really have to make sure that this happens a little bit more often.
Whether it's a podcast or whether we just meet each other at your wonderful offices where I can see behind you.
So thank you for your time.
It was an absolute pleasure.
The hour and a bit flew, I have to say.
And that's always a great sign.
I really appreciate this.
I think you're... Sofinova is a key player in the space.
And I've really enjoyed your...
Vanguards of Healthcare by Bloomberg Intelligence · Fosun Pharma’s Drive Beyond China · 17 Nov 2025
podcast
Welcome to another episode of Bloomberg Intelligence, Vanguards of Healthcare podcast, where we speak with the leaders at the forefront of change in the healthcare industry.
My name is Sam Fazelli, and I'm a senior pharmaceuticals analyst at Bloomberg Intelligence, the in-house research arm of Bloomberg.
Showing 501–520 of 906 · page 26 of 46
← Previous
Next →